First-in-human KT501 for rheumatoid arthritis
Official title: A Phase 1a, Open-Label, First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KT501 by a Single Subcutaneous Administration in Participants With Rheumatoid Arthritis
Run by Kali Therapeutics, Inc. · NCT07234773 · Data updated 2026-11-12
This Phase 1, open-label test will give a single under-the-skin dose of KT501 to adults with moderate to severe rheumatoid arthritis to see if it is safe and how it acts in the body.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | Kali Therapeutics, Inc. Industry-sponsored |
| Locations | 1 site (Bayswater) |
| Status | Recruiting |
| Started | March 6, 2026 |
| Main results expected | February 2027 |
| Study ends | August 2027 |
| Registry record updated | March 10, 2026 |
| Trial ID | NCT07234773 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 with adult-onset RA for at least 6 months, moderately to severely active disease, RF+ or ACPA+, who have had inadequate response to prior therapy and can attend study visits and remain on stable DMARDs are ideal candidates.
✕Probably not a fit
Patients with ACR functional class IV, other concomitant autoimmune diseases, active or recurrent serious infections, recent malignancy, organ transplant history, recent live vaccination, or recent major surgery are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1, open-label, first-in-human dose-escalation trial of a single subcutaneous administration of KT501 in people with rheumatoid arthritis. Up to five dose cohorts will enroll approximately 24 participants in total, with all participants dosed on Day 1 and followed for safety, pharmacokinetics (PK), and pharmacodynamics (PD). Primary outcomes focus on safety and tolerability, with PK/PD sampling to characterize how the drug is processed and its biological effects, including B-cell changes. Most participants are followed to Week 12, with extended B-cell monitoring to Week 48 for those with lowered B-cell counts.
Why it matters
Potential benefit: If successful, KT501 could provide a new targeted way to reduce B cells and lower disease activity with a single subcutaneous dose.
How similar studies have gone: B-cell depletion therapies such as rituximab have proven effective in RA, but first-in-human T-cell engager approaches like KT501 are novel and have not yet been tested in patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 to 75 years old 2. Diagnosis of adult-onset RA for at least 6 months 3. Moderately to severely active RA 4. Inadequate treatment response as defined in the protocol 5. RF + or ACPA+ 6. Stable use of traditional DMARDs is permitted 7. Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions. Exclusion Criteria: 1. Functional class IV as defined by the ACR Classification of Functional Status in RA 2. Presence of any concomitant autoimmune disease other than RA 3. Active infection, history of serious recurrent or chronic infection 4. History of progressive multifocal leukoencephalopathy 5. Have a diagnosis or history of malignant disease within 5 years or breast cancer diagnosed within the previous 10 years. 6. History of or planned organ transplant and/or autologous or allogeneic hematopoietic stem cell transplantation 7. Receipt of live vaccine within 4 weeks 8. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after study 9. Women who are pregnant or breastfeeding 10. Significant or uncontrolled medical disease that would preclude participant participation
Where it's running
-
Kali Study Site
Bayswater, Australia Recruiting
Study contacts
- Study coordinator: Trial Information
- Email: clinical@kalitherapeutics.com
- Phone: 1-858-888-3080
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Heart Rate Variability and Rheumatoid Arthritis: What HRV Looks Like with RA
This study checks whether continuous HRV data from an Oura ring can reflect RA disease activity in adults with RA.
-
Discontinuing MTX or LEF in RA Patients on TNF Inhibitors
This trial tests whether stopping methotrexate or leflunomide while continuing a TNF inhibitor is not worse for disease control in adults with rheumatoid arthritis.
-
FT839 therapy for autoimmune diseases
This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.
-
24-Hour Movement and Atherosclerotic Risk in adults with rheumatoid arthritis
This study tests how daily activity, sitting, and sleep relate to heart-related risk in adults with RA, using wearables and follow-up after a year.
-
Integrative AI profiling of chronic RA pain
This study tests whether an AI-driven multiomic and neurophysiological approach can help explain and predict persistent pain in adults with active rheumatoid arthritis.
-
Oxidative Stress and Heart Risk in People with Rheumatoid Arthritis
This study tests whether certain markers of oxidative stress in people with rheumatoid arthritis are linked to subclinical atherosclerosis and arterial stiffness, which could relate to future heart disease risk.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.